Sensitivity to Activated Protein C; Influence of Oral Contraceptives and Sex

Summary We investigated sensitivity to activated protein C (APC) in 43 men, 42 women not using oral contraceptives (OC) and 38 women using OC containing 30.0-37.5 μg ethinyl estradiol. A commercially available kit was used. Men were more sensitive to APC as compared with women not using OC (p <0.005), but this difference seems not to be of clinical importance. Women using OC showed to be significantly less sensitive to APC, reflected by a lower APC-ratio, as compared with men (p <0.005) and women not using OC (p <0.05). So, in normal individuals the APC-sensitivity differs according to sex and estrogen intake. This should be taken into account when interpreting APC-ratios.

[1]  B. Dahlbäck,et al.  Multicenter Evaluation of a Kit for Activated Protein C Resistance on Various Coagulation Instruments Using Plasmas from Healthy Individuals , 1994, Thrombosis and Haemostasis.

[2]  J. Voorberg,et al.  Association of idiopathic venous thromboembolism with single point-mutation at Arg506 of factor V , 1994, The Lancet.

[3]  B. Dahlbäck,et al.  Linkage between inherited resistance to activated protein C and factor V gene mutation in venous thrombosis , 1994, The Lancet.

[4]  B. Evatt,et al.  Activated protein C resistance caused by Arg506Gln mutation in factor Va , 1994, The Lancet.

[5]  Pieter H. Reitsma,et al.  Mutation in blood coagulation factor V associated with resistance to activated protein C , 1994, Nature.

[6]  B. Dahlbäck,et al.  Resistance to activated protein C as a basis for venous thrombosis. , 1994, The New England journal of medicine.

[7]  B. Dahlbäck,et al.  Inherited resistance to activated protein C is corrected by anticoagulant cofactor activity found to be a property of factor V. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[8]  F. Rosendaal,et al.  Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study , 1993, The Lancet.

[9]  J. Griffin,et al.  Anticoagulant protein C pathway defective in majority of thrombophilic patients. , 1993, Blood.

[10]  B. Dahlbäck,et al.  Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[11]  G. Rodgers,et al.  Laboratory and clinical aspects of inherited thrombotic disorders , 1992, American journal of hematology.

[12]  E. Daume.  Influence of modern low-dose oral contraceptives on hemostasis. , 1990, Advances in contraception : the official journal of the Society for the Advancement of Contraception.

[13]  J. Bonnar.  Coagulation effects of oral contraception. , 1987, American journal of obstetrics and gynecology.

[14]  L. Boerger,et al.  Oral contraceptives and gender affect protein S status. , 1987, Blood.

[15]  F. Beller,et al.  Effects of Oral Contraceptives on Blood Coagulation. A Review , 1985, Obstetrical & gynecological survey.

[16]  C. Esmon,et al.  Familial protein S deficiency is associated with recurrent thrombosis. , 1984, The Journal of clinical investigation.

[17]  F. Walker.  Protein S and the Regulation of Activated Protein C , 1984, Seminars in thrombosis and hemostasis.

[18]  R. Bertina,et al.  Congenital protein C deficiency and venous thromboembolism. A study of three Dutch families. , 1983, The New England journal of medicine.

[19]  M. Doder,et al.  [Effect of oral contraceptives on blood coagulation]. , 1971, Srpski arhiv za celokupno lekarstvo.

[20]  R. Marlar,et al.  Mechanism of action of human activated protein C, a thrombin-dependent anticoagulant enzyme. , 1982, Blood.